Core Viewpoint - The company emphasizes steady operations and enhancing core competitiveness as fundamental principles, aiming to solidify intrinsic value and improve market representation of its value for better investor returns [1] Group 1: Company Strategy - The company is committed to optimizing corporate governance and enhancing information disclosure [1] - The company focuses on investor relations management and increasing cash dividends as part of its market value management efforts [1] Group 2: Goals and Commitments - The company aims to continuously improve its intrinsic value and strive for a more reasonable market reflection of its value [1] - The company is dedicated to providing better returns for investors through its strategic initiatives [1]

（文章来源：证券日报） 证券日报网讯 1月19日，海普瑞在互动平台回答投资者提问时表示，公司以患者临床未满足的需求为 始，通过多种研发模式布局了高度创新的临床管线，并正在积极推进各项新药开发进程。新药研发具有 周期长、投入大、风险高的特点，临床过程和结果存在诸多不确定性，如有重大进展，公司将及时履行 信息披露义务。 ...

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares) [2]. - The main business segments include heparin sodium raw materials, low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization is 18.048 billion yuan, with a trading volume of 87.8751 million yuan and a turnover rate of 0.57% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 12.0093 million shares, an increase of 691,700 shares from the previous period [9]. Technical Analysis - The average trading cost of the stock is 11.62 yuan, with the current price approaching a resistance level of 12.37 yuan, indicating potential for upward movement if the resistance is broken [6].

Group 1 - The company, Haiprui (002399), indicated that specific operating performance for the year 2025 will be detailed in its annual report for that year [1] - The company's stock price is influenced by various factors, and it aims to enhance communication with capital market investors [1] - The company is committed to better reflecting its intrinsic value in the market capitalization performance, striving to provide better returns for investors [1]

来源：新浪证券-红岸工作室 1月13日，海普瑞涨0.73%，成交额7838.59万元，换手率0.50%，总市值182.38亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 4、根据2024年年报，公司海外营收占比为93.04%，受益于人民币贬值。 区间今日近3日近5日近10日近20日主力净流入264.46万-158.62万-28.93万-587.36万-643.10万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1698.58万，占总成 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 深圳市海普瑞藥業集團股份有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09989 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 220,094,500 | | 0 | | 220,094,500 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 220,094,500 | | 0 | | 220,094,500 | | 1. 股份分類 | 普通股 | 股份類別 | H ...

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and strong overseas revenue [2][3]. Company Overview - Established in 1998 and listed in 2010, Hepalink's main business includes the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The company's revenue composition is as follows: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [7]. - As of September 30, 2025, Hepalink achieved a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company's overseas revenue accounts for 93.04%, benefiting from the depreciation of the RMB [3]. - The total market capitalization is 17.079 billion yuan, with a trading volume of 31.2621 million yuan and a turnover rate of 0.22% [1]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed in the last three years [8]. Institutional Holdings - As of September 30, 2025, the eighth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 12.0093 million shares, an increase of 691,700 shares compared to the previous period [9]. Market Activity - The stock experienced a slight decline of 0.26% on December 17, with a net inflow of 429,600 yuan from major investors, representing 0.02% of the total [4][5].

Core Viewpoint - On December 16, 2025, the company announced the election of Mr. Zhang Ping as the employee director of the sixth board of directors through a democratic voting process by the employees [1] Group 1 - The board of directors received a notification from the company's labor union regarding the election [1] - Mr. Zhang Ping's position in the board was changed from non-independent director to employee director [1] - The term of Mr. Zhang Ping as employee director will last until the end of the sixth board's term [1]

深圳市海普瑞藥業集團股份有限公司 章程 1 目錄 | 第一章 | 總則 | | --- | --- | | 第二章 | 經營宗旨和範圍 | | 第三章 | 股份 | | 第一節 | 股份發行 | | 第二節 | 股份增減和回購 | | 第三節 | 股份轉讓 | | 第四章 | 股東和股東會 | | 第一節 | 股東 | | 第二節 | 控股股東和實際控制人 | | 第三節 | 股東會的一般規定 | | 第四節 | 股東會的召集 | | 第五節 | 股東會的提案與通知 | | 第六節 | 股東會的召開 | | 第七節 | 股東會的表決和決議 | | 第八節 | 類別股東表決的特別程序 | | 第五章 | 董事和董事會 | | 第一節 | 董事的一般規定 | | 第二節 | 董事會 | | 第三節 | 獨立董事 | | 第四節 | 董事會專門委員會 | | 第六章 | 高級管理人員 | | 第七章 | 財務會計制度、利潤分配和審計 | | 第一節 | 財務會計制度 | | 第二節 | 內部審計 | | 第三節 | 會計師事務所的聘任 | | 第八章 | 通知和公告 | | 第一節 | 通知 | | 第二節 | 公 ...

Core Viewpoint - The company announced the election of Mr. Zhang Ping as the employee director of the sixth board of directors, reflecting a democratic process within the organization [1] Group 1 - The board received a notification from the company’s labor union regarding the election [1] - Mr. Zhang Ping's position was adjusted from non-independent director to employee director [1] - His term will last until the end of the sixth board's tenure [1]